Health Claim. Digestive disorders




Clinical trial

Regulatory approval


Product Launch


PREVIPECT is a new prebiotic developed by GoodGut as a complement to the treatment of Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).

Current situation: problems and needs

  • Intestinal diseases have a high incidence and a chronic and severe impact on the lives of affected patients.
  • The gut microbiome of IBS and IBD patients differs from healthy subjects and shows pathological dysbiosis.
  • Probiotic treatment to restore balance and improve the course of the disease works in the short term but it is insufficient to restore dysbiosis in the long term.

There is the need for complementary tools capable of restoring intestinal balance in the long term in patients with digestive diseases.

Our Proposal

The prebiotic of GoodGut, with beneficial properties for patients with IBD and IBS, is a non-digestible fiber which has been developed to induce the selective growth of the protective bacteria. This increases their immunoprotective activity, such as the production of volatile fatty acids. In addition, it provides several advantages compared to probiotics:

  • Increased treatment efficacy
  • Does not require refrigeration
  • Balances dysbiosis and increases most proactive anaerobic bacteria, which are not present in probiotics.

PREVIPECT has been assessed in a pilot study with fecal samples from 18 patients with IBD, IBS, and health subjects. The study consisted of evaluating the effect of the prebiotic on the fecal microbiota. It was carried out in collaboration with Hospital Universitari de Girona Dr. Josep Trueta. In addition, we completed theIn Vitrotoxicity test. For more information, you can check the results published in the study here(Oliver L. et al, 2021).

In order to validate the results observed in the pilot study, and demonstrate the benefits and added value of PREVIPECT in subjects with intestinal diseases such as IBD or IBS, the next step is to conduct clinical trials with the different target populations. With this, we plan to launch the product to the market in 2022.

Are you a healthcare or laboratory professional?

You are accessing the website, aimed at disseminating technical information on the diagnosis of digestive diseases.

The information contained on this page is intended exclusively for healthcare and/or laboratory professionals with the ability to diagnose digestive diseases and/or analyse the microbiota, which a specialized training is required for its correct interpretation. If you are not a qualified healthcare and/or laboratory professional, GoodGut is not responsible for any prejudice you may suffer from decisions based on the content of this page or any of its links. The information provided to serves to support, not replace, the relationship that exists between a patient/visitor of this website and their physician.